Andrew Jack

Physicians in two specialties receive more money from the pharmaceutical industry than their counterparts in other branches of medicine, according to new data analysis.

Patient groups are hailing a new era of transparency in drug development and clinical trials, but drug companies fear that the publication of so much trial data could damage their business models.